Belgian radiopharmaceutical firm Ion Beam Applications (IBA) has signed a collaboration agreement with molecular imaging and therapy developer NeuroSurvival Technologies (NST) of Petach-Tikva, Israel.
The agreement calls for radiolabeling and distribution of NST's ApoSense 18F-ML-10 molecular imaging agent for apoptosis to sites participating in multicenter clinical trials, according to IBA of Louvain-la-Neuve, Belgium.
Related Reading
IBA, Lantheus ink radiopharma deal, July 31, 2008
IBA, Wilex ink licensing pact, June 6, 2008
IBA finalizes acquisition of CIS bio, May 30, 2008
IBA opens U.K. production center, March 14, 2008
NST is cleared for ApoSense trials, July 25, 2008
Copyright © 2008 AuntMinnie.com
